COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19
Latest Information Update: 01 Jun 2023
At a glance
- Drugs Acebilustat (Primary) ; Camostat mesilate (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms COPPS-Master-Protocol
- 28 Mar 2023 Status changed from active, no longer recruiting to completed.
- 12 Sep 2022 Planned End Date changed from 1 Aug 2022 to 1 Jan 2023.
- 12 Sep 2022 Status changed from recruiting to active, no longer recruiting.